Posts

Posted on

Trovo and Allied Esports Team Up for Mobile Tournaments in December

Trovo and Allied Esports Team Up for Mobile Tournaments in December

“Trovo Holiday Royale” to Feature Three Battle Royale Duos Competitions in Nine Days with More Than $50,000 in Prizes for Players and Rewards for Viewers

LAS VEGAS–(BUSINESS WIRE)–
Allied Esports, a global esports entertainment company (“Allied Esports”) and a subsidiary of Allied Esports Entertainment, Inc. (NASDAQ: AESE), and interactive live streaming platform Trovo have announced the creation of the Trovo Holiday Royale, three $10,000 mobile esports tournaments featuring popular Battle Royale games – Fortnite, PLAYERUNKNOWN’S BATTLEGROUNDS (PUBG) Mobile and Call of Duty Mobile – starting December 20, 2020.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201217005366/en/

Organized by Trovo and co-organized and produced by Allied Esports from the HyperX Esports Arena Las Vegas, the nine days of mobile duos tournaments will be divided into three days of competition for each game, with public matchmaking for Open Qualifiers on day one followed by two days of custom lobbies for Closed Qualifiers and the Finals.

The Trovo Holiday Royale starts with Fortnite from December 20-22, continues with PUBG Mobile on December 23 and December 26-27, and concludes with Call of Duty Mobile from December 28-30. All competition and live streams will begin at 12 p.m. PT, except for the December 27 PUBG Mobile Finals, which will begin at 3 p.m. PT. The Closed Qualifiers and $10,000 Finals for each tournament will be streamed live on Trovo.live/TrovoHolidayRoyale.

“To celebrate the holidays and wrap up our first official calendar year, we are excited to bring some competitive fun to the entire Trovo community with the Trovo Holiday Royale,” said Allen Chan, Senior Operations Manager at Trovo. “With streamers able to win prizes and rewards allotted for viewers, we are ecstatic to work with Allied Esports to deliver this unique tournament and entertainment concept to the Trovo family.”

“The Trovo Holiday Royale is an exciting opportunity to reward Trovo’s most loyal and active community members, while inviting new users to experience the platform in a competitive and entertaining way,” said Frank Ng, CEO of Allied Esports Entertainment. “We’re thrilled to partner our esports organization and production experience with Trovo’s growing platform and look forward to exploring more opportunities to work together in the new year.”

Prize Pool, “Trovo Treasure” and Viewer Rewards

Each Trovo Holiday Royale tournament will feature a $10,000 prize pool that will pay out the top eight teams, with $5,000 awarded to the top performing duo, $2,000 going to the second-place team, $1,000 awarded to the third-place finishers and $600 going to the duo in fourth place. Fifth- and sixth-place teams will receive $500 each while seventh- and eighth-place finishers will earn $200 each.

The Trovo Holiday Royale will offer participants the opportunity to earn “Trovo Treasure,” a cash reward system totaling more than $24,000 across the three tournaments. The 200 players who advance to the Closed Qualifiers of each tournament will receive $15 cash and those who move on to the Finals will be awarded an additional $50 cash.

But the Trovo Holiday Royale is not just about the players; fans who tune in to watch the tournament will have a chance to enjoy rewards as well. Fans who watch their favorite Trovo streamers during each tournament or tune in to Trovo.live/TrovoHolidayRoyale and participate in the chat will have the chance to receive subscriptions to their Trovo channel. The Allied Esports Trovo account will randomly gift 200 subscriptions during the Closed Qualifiers of each tournament and 400 subscriptions during the Finals of each tournament.

Player Eligibility and Format

To participate in the Trovo Holiday Royale tournaments, players must:

  • Have an active Trovo account,
  • Register with Allied Esports on Smash.gg,
  • Join the Allied Esports Discord, and
  • Have one duo member stream their competitive play on Trovo throughout the tournament.

For Open Qualifiers of each tournament, all participants will queue in a duos matchmaking lobby during a three-hour window and play in as many games as possible, earning points for placement and eliminations. Each duo will submit their top three scores within the three-hour window, which will be combined to create their qualifying score. The top 84 scores from Open Qualifiers will advance to the next round of the tournament.

In addition to the teams that advanced from Open Qualifiers, Closed Qualifiers will include 16 Trovo Streamers with Trovo Level 1 status or greater who apply at AlliedEsports.gg/TrovoHolidayRoyale and receive an invitation from Trovo for direct entry. Invited players may choose their own duo partner. The Closed Qualifiers will be split into two 50-team (100-player) custom lobbies where participants will compete in three rounds of play to accumulate the best combined score.

The top 34 scores from Closed Qualifiers will join an additional 16 invited Trovo streamers who have Trovo Level 1 status, plus 15-plus hours streamed on Trovo in the month of December, and their duo partner for the Finals of the Trovo Holiday Royale. All Finals players will participate in five rounds of custom lobby matches to accumulate the best combined score.

The Trovo Holiday Royale is limited to participants in North America and Latin America only. Fans can use #TrovoRoyale on Twitter and Instagram to join the conversation and learn more leading up to and throughout the tournaments. Visit AlliedEsports.gg/TrovoHolidayRoyale for official tournament rules.

About Allied Esports

Named one of the World’s Most Innovative Companies by Fast Company, Allied Esports International, Inc. is at the forefront of esports entertainment with a global network of properties designed to serve as competition battlegrounds, community experience hubs and content production centers.

Through direct operation or membership in the Allied Esports Property Network, the world’s first esports affiliate program, Allied Esports’ facilities span North America, Europe, China and Australia, and include the world-renowned HyperX Esports Arena Las Vegas, a fleet of mobile arenas, the HyperX Esports Trucks, and the HyperX Esports Studio in Hamburg, Germany.

Allied Esports’ properties serve as the home to a number of online and offline proprietary productions and events, including Friday Frags and Saturday Night Speedway, as well as original partner programs like the Simon Cup.

For more information about Allied Esports, visit AlliedEsports.gg and follow @AlliedEsports. Allied Esports International, Inc. is a subsidiary of Allied Esports Entertainment, Inc.

About Allied Esports Entertainment

Allied Esports Entertainment, Inc. (NASDAQ: AESE) is a global leader in esports entertainment, providing innovative infrastructure, transformative live experiences, multiplatform content and interactive services to audiences worldwide through its strategic fusion of two powerful brands: Allied Esports and the World Poker Tour (WPT). For more information, visit AlliedEsportsEnt.com.

About Trovo

Trovo is an interactive live streaming platform for gamers and the things we love. It is a unique platform to watch and chat with other fans from all over the world. You can see the hottest games in action, share your own gaming experience, and join in an entertaining community created especially for gamers, creators and do-ers. Trovo is where players, gamers, viewers and streamers get to know each other in new ways. With Trovo, you can: Watch streams of your favorite games and content creators with a smooth experience on both computers and mobile devices; Browse and explore streams of the most popular games and get recommendations on content customized for you; Interact with streamers and other viewers by chatting, casting spells and sending emotes in the chatroom; Support your favorite streamers by following and subscribing them and receive their real time updates; and Customize your profile and personal page so that other users can get to know you.

For more information about Trovo, visit trovo.live and download the app in the App Store and Google Play Store. Follow @trovolive on all social platforms to stay up to date on all the latest news.

Forward Looking Statements

This press release includes “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of us, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include: our ability to execute on our business plan; our ability to retain key personnel; general economic and market conditions impacting demand for our products and services; adequacy of our funds for future operations; our future expenses, revenue and profitability; our ability to develop new products; our dependence on key suppliers, manufacturers and strategic partners; and industry trends and the competitive environment in which we operate. These and other risk factors are discussed in our reports filed with the Securities and Exchange Commission. We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Media Contacts:

Brian Fisher

Allied Esports

[email protected]

Allen Chan

Trovo Live

[email protected]

Investor Contact:

Lasse Glassen

Addo Investor Relations

[email protected]

424-238-6249

KEYWORDS: Nevada United States North America

INDUSTRY KEYWORDS: Entertainment Technology Online Events/Concerts Software Internet Electronic Games

MEDIA:

Logo
Logo
Logo
Logo
Posted on

Henry Schein Medical Helps Automate and Streamline Patient Waiting Room Process With Yosi Health

Henry Schein Medical Helps Automate and Streamline Patient Waiting Room Process With Yosi Health

New Digital Patient Intake Solution to Help Minimize Wait Times and Improve Patient Experience Amid COVID-19 Resurgence

MELVILLE, N.Y.–(BUSINESS WIRE)–
Henry Schein Medical, the U.S. medical business of Henry Schein, Inc., recently entered into a distribution agreement with Yosi Health, a provider of digital patient scheduling, registration, payment, and communication cloud-based software solutions. For physicians and patients looking for a streamlined waiting room process, Yosi Health’s patient intake solution, Yosi Intake, can create a contactless waiting room by enabling patients to register at home, helping to improve the patient experience and reduce administrative costs for the practice.

Integrated with industry-leading electronic medical record (EMR) and practice management solutions, Yosi Intake and Henry Schein can help deliver a customizable digital solution for scheduling and document management, as well as co-pays and payments.

“Henry Schein Medical is committed to selecting best-in-class solutions that can help modernize the traditional patient visit and automate routine administrative tasks,” said Michael Casamassa, Vice President, Solutions and Planning, Henry Schein Medical. “With the addition of Yosi Health to our SolutionsHub™, providers can rely on us to help meet patient expectations for quick, contactless visits without sacrificing quality care.”

As a result of this partnership, Yosi Health expands Henry Schein Medical’s SolutionsHub to help fulfill the clinical, financial, and operational needs of primary care physicians and specialists, group practices, physician-owned labs, ambulatory surgery centers, and Integrated Delivery Networks (IDNs)/Health Systems. The creation of the SolutionsHub was a result of thousands of business discovery meetings across the United States where customers provided feedback about areas of their business that they would like to improve, and together with third-party providers, Henry Schein Medical identified new customizable solutions to help create practice efficiencies.

“Being selected to join Henry Schein’s SolutionsHub is truly an honor and an affirmation that Yosi Health is being recognized by the industry for modernizing the patient experience for health care practices nationwide,” said Yosi Health’s CEO, Hari Prasad. “Unlike the traditional kiosk or tablet solutions available in the market, our pre-registration capabilities can help patients feel safe and ensure critically important health care appointments are not missed or avoided. We are proud to do our part in supporting front-line health care workers.”

To find out more about how Yosi Intake, and other solutions from Yosi Health, can benefit your practice, visit https://www.henryscheinsolutionshub.com/solutions/operational/online-scheduling/yosi-health/

About Henry Schein, Inc.

Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 19,000 Team Schein Members worldwide, the Company’s network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.

Henry Schein operates through a centralized and automated distribution network, with a selection of more than 120,000 branded products and Henry Schein private-brand products in stock, as well as more than 180,000 additional products available as special-order items.

A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 31 countries. The Company’s sales from continuing operations reached $10.0 billion in 2019, and have grown at a compound annual rate of approximately 13 percent since Henry Schein became a public company in 1995.

For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, and @HenrySchein on Twitter

About Yosi Health:

Yosi Health creates customizable, cloud-based solutions that modernize care center administration and improve the patient experience. Their premier product, Yosi Intake, is a pre-arrival focused patient intake and registration system that is eliminating wait times, improving patient experience and increasing financial results for large health systems and busy care centers by engaging patients through the entire care journey. For more information, visit Yosi Health at https://www.yosi.health/

Ann Marie Gothard

Vice President, Corporate Media Relations

[email protected]

(631) 390-8169

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Technology Hospitals Other Technology Software Practice Management Other Health General Health Health Supply Chain Management Retail

MEDIA:

Logo
Logo
Posted on

Revance Reports Positive Efficacy and Duration Results from Phase 2 Upper Facial Lines Study

Revance Reports Positive Efficacy and Duration Results from Phase 2 Upper Facial Lines Study

– Open-label study of DaxibotulinumtoxinA for Injection in the combined treatment of glabellar lines, forehead lines and crow’s feet lines showed efficacy of none or mild wrinkle severity in at least 92 percent of subjects at Week 4 –

– Median time to return to baseline wrinkle severity was at least 33 weeks (7.6 months) –

– Treatment with DaxibotulinumtoxinA for Injection was well tolerated across upper facial regions –

NEWARK, Calif.–(BUSINESS WIRE)–
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced positive topline efficacy and safety results from its Phase 2 multicenter, open-label study of investigational drug candidate DaxibotulinumtoxinA for Injection for the combined treatment of upper facial lines, which are comprised of glabellar (frown) lines (GL), dynamic forehead lines (FHL) and lateral canthal lines (LCL), commonly known as crow’s feet lines.

In the Phase 2 study, 48 subjects were enrolled to receive a single treatment of DaxibotulinumtoxinA for Injection with a total study duration of 36 weeks. Subjects received 40, 32, and 48 units of DaxibotulinumtoxinA for Injection respectively in the glabellar complex, forehead and lateral canthal areas.

TREATMENT EFFECT

The key endpoints for efficacy were the proportion of subjects achieving a score of none or mild wrinkle severity at maximum contraction (maximum frown, eyebrow elevation, and smile effort) at Week 4, as assessed on the Investigator Global Assessment Frown Wrinkle Severity (IGA-FWS), Investigator Global Assessment Forehead Wrinkle Severity (IGA-FHWS), and Investigator Global Assessment Lateral Canthal Wrinkle Severity (IGA-LCWS), respectively.

 

Proportion of subjects achieving a score of none or mild at Week 4

Glabellar lines

95.8 percent

Forehead lines

95.8 percent

Lateral canthal lines

91.7 percent

The study measured duration of effect in responders (those who achieved a score of none or mild at Week 4). These duration measures were defined as the median time to return to baseline wrinkle severity or the time to loss of none or mild wrinkle severity, both based on investigator and subject assessments.

 

Median time to return to baseline

Median time to loss of none or mild

Glabellar lines

 

33.3 weeks

 

25.0 weeks

Forehead lines

 

35.3 weeks

 

24.0 weeks

Lateral canthal lines

 

35.2 weeks

 

28.1 weeks

SAFETY RESULTS

DaxibotulinumtoxinA for Injection was generally safe and well tolerated when all three facial areas were injected simultaneously. There were no treatment-related serious adverse events (SAEs). The most common adverse events (AEs) were injection site erythema (6.3 percent), facial discomfort (4.2 percent) and headache (2.1 percent). No eyelid or brow ptosis was reported.

PATIENT SATISFACTION RESULTS

Participants used a 7-point Subject Global Satisfaction with Treatment Questionnaire to rate their satisfaction with treatment of DaxibotulinumtoxinA for Injection. At Week 4, 100 percent of participants reported being at least “Somewhat Satisfied” with the treatment in all three areas, and 83.0 percent, 78.7 percent, and 80.9 percent reported being “Very Satisfied” with the treatment of their glabellar lines, forehead lines, and crow’s feet, respectively.

“The positive results reported today are reflective of the real-world applications of neuromodulators in the upper face and provide an enhanced understanding of the safety and efficacy of DaxibotulinumtoxinA for Injection in the combined treatment of glabellar lines, forehead lines and lateral canthal lines,” said Roman Rubio, M.D., Senior Vice President of Clinical Development at Revance. “This full upper face data complements our already reported results from individual dose-ranging studies, and further expands the body of knowledge on our next-generation neuromodulator. As we saw in our other aesthetic and therapeutic clinical trials, DaxibotulinumtoxinA for Injection delivered a meaningful duration of effect, ranging from 24 to 35 weeks, depending on the measure used and indication studied, while being generally well tolerated by patients.”

“Many of my patients are looking for a more enduring treatment of their upper facial lines and wrinkles, as currently available neuromodulators typically only last 10 to 16 weeks, depending on the location within the face,” said study investigator Jeffrey S. Dover, MD, FRCPC, co-director of SkinCare Physicians in Chestnut Hill, MA. “I am pleased to see the high patient satisfaction scores for DaxibotulinumtoxinA for Injection and expect a treatment regimen of just two times a year could be a welcome benefit to patients looking for long-lasting treatment.”

Phase 2 Clinical Program in Upper Facial Lines

Revance’s Phase 2, multicenter, open-label study to evaluate the efficacy and safety of DaxibotulinumtoxinA for Injection for the combined treatment of upper facial lines – glabellar (frown) lines, dynamic forehead lines, and lateral canthal lines, or crow’s feet – was conducted at eight sites in the United States and Canada and enrolled 48 subjects, 18 years of age and above. Patients received a single DaxibotulinumtoxinA for Injection treatment of 40 units in five sites of the glabella, 32 units in four sites of the forehead and 48 units in six sites (three on each side) of the lateral canthus. After treatment on Day 1, subjects were followed for a minimum of 24 weeks and up to 36 weeks.

This trial was undertaken in addition to two Phase 2a open-label, dose escalation studies of DaxibotulinumtoxinA for Injection in the treatment of forehead lines following glabellar line injections and crow’s feet lines injections. Revance announced positive results from the Phase 2a studies in June 2020. Interim Week 4 data from the Phase 2a studies in forehead lines and crow’s feet were used in the final design of this upper facial lines Phase 2 study to optimize dosing and injection patterns.

In December of 2018, Revance completed a successful SAKURA Phase 3 program for DaxibotulinumtoxinA for Injection in the treatment of glabellar lines, reporting high response rates and 24-weeks duration of effect, based on a median time to loss of none or mild of wrinkle severity. Revance is currently awaiting a decision on the approval of DaxibotulinumtoxinA for Injection for the treatment of glabellar lines by the U.S. Food and Drug Administration, pending a manufacturing site inspection, which was delayed due to COVID-19 travel restrictions.

More information about the Phase 2 study can be found at www.clinicaltrials.gov.

About Revance Therapeutics, Inc.

Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval. Revance is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow’s feet, as well as in two therapeutic indications – cervical dystonia and adult upper limb spasticity. To accompany DaxibotulinumtoxinA for Injection, Revance owns a unique portfolio of premium products and services for U.S. aesthetics practices, including the exclusive U.S. distribution rights to the RHA® Collection of dermal fillers, the first and only range of FDA-approved fillers for correction of dynamic facial wrinkles and folds, and the HintMD fintech platform, which includes integrated smart payment, subscription and loyalty digital services. Revance has also partnered with Viatris (formerly Mylan N.V.) to develop a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. Revance is dedicated to making a difference by transforming patient experiences. For more information or to join our team visit us at www.revance.com.

“Revance Therapeutics” and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.

BOTOX® is a registered trademark of Allergan, Inc.

Forward-Looking Statements

Any statements in this press release that are not statements of historical fact, including statements about the commercial potential of DaxibotulinumtoxinA for Injection; the potential value and application of DaxibotulinumtoxinA for Injection in neuromodulator indications; the process and timing of, and ability to complete, current and anticipated future clinical development of our investigational drug product candidates; our ability to obtain, and the timing relating to, regulatory approval with respect to our drug product candidates, including with respect to the anticipated approval of DaxibotulinumtoxinA for Injection in glabellar lines; the rate and degree of commercial interest and acceptance; development of a biosimilar to BOTOX®; our business strategy, timeline and other goals for our anticipated products, plans and prospects, including our commercialization plans; and potential benefits of our drug product candidates, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance, events, circumstances or achievements reflected in the forward-looking statements will ever be achieved or occur.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties relate, but are not limited to: the uncertain clinical development process; the risk that clinical trials may not have an effective design or generate positive results; the applicability of clinical study results to actual outcomes; the rate and degree of commercial acceptance and our ability to successfully commercialize DaxibotulinumtoxinA for Injection, if approved, and the timing and cost of commercialization activities; the status of commercial collaborations; the results and timing of our regulatory approvals; delays in the approval of our BLA for DaxibotulinumtoxinA for Injection for the treatment of glabellar lines due to COVID-19-related policies and travel restrictions currently in place at the FDA; the impact of the COVID-19 pandemic on our manufacturing operations, supply chain, end user demand for our products, commercialization efforts, business operations, clinical trials and other aspects of our business; our ability to obtain funding for our operations; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; and our financial performance, including future revenue, expenses and capital requirements. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in our periodic filings with the Securities and Exchange Commission (SEC), including factors described in the section entitled “Risks Factors” on our Form 10-Q filed with the SEC on November 9, 2020. The forward-looking statements in this press release speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

Investors

Revance Therapeutics, Inc.:

Jeanie Herbert, 714-325-3584

[email protected]

Jessica Serra, 626-589-1007

[email protected]

Gilmartin Group, LLC.:

Laurence Watts, 619-916-7620

[email protected]

Media

Revance Therapeutics, Inc.:

Sara Fahy, 949-887-4476

[email protected]

General Media:

Goodfuse:

Jenifer Slaw, 347-971-0906

[email protected]

Trade Media:

Nadine Tosk, 504-453-8344

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Cosmetics Retail Health Other Health Clinical Trials Pharmaceutical Biotechnology

MEDIA:

Posted on

Fathom Holdings Enters Michigan Market

— Now Operating in 27 States and 113 Local Markets —

PR Newswire

CARY, N.C., Dec. 17, 2020 /PRNewswire/ — Fathom Holdings Inc. (NASDAQ: FTHM), a holding company that primarily operates through its wholly owned subsidiary, Fathom Realty, LLC, a national, cloud-based, technology-driven, residential real estate brokerage, today announced that it has entered the Michigan market. The company now operates in 27 states and 113 local markets.

With a newly obtained license to operate in Michigan, Fathom initially is focusing on 17 communities, comprising five of the most populous cities in the state, including Dearborn, Livonia and Farmington Hills.

Fathom also announced it has hired Kay Ready as its Southeast Michigan District Director. Ready has more than 25 years of sales experience, including eight years in residential real estate. Earlier in her career, she was a District Sales Manager at Avon. As a manager, Ready uses her expertise to educate agents on how to transform their lives by building relationships, realizing their value, elevating their thinking, and living purposefully.  

“Entering Michigan brings us another step closer to our goal of serving every state in the country,” said Fathom CEO, Joshua Harley. “Expected growth in Michigan’s population over the next five years should contribute to continued increased housing demand in the state.  We’re excited to have Kay leading the charge, and we welcome her to the Fathom family.

“Our ability to enter new markets efficiently gives us a strong platform for geographic expansion.   We plan to continue identifying new markets, while also using our unique commission structure and strong culture to recruit new agents and residential real estate brokerage firms. Our team is successfully executing our long-term plan, and we believe we remain on the right track to deliver increasing value to all of our stakeholders,” Harley added.

About Fathom Holdings Inc.

Fathom Holdings Inc. is the parent company of Fathom Realty Holdings, LLC, a national, virtual, full-service real estate brokerage that leverages proprietary cloud-based software called IntelliAgent to operate a Platform as a Service model (PaaS) for the residential real estate industry.  Fathom offers real estate professionals 100% commission, small flat-fee transaction costs, support, technology, and training, all powered by best in class operational efficiencies. For more information visit www.fathomrealty.com.

Cautionary Note Concerning Forward-Looking Statements

This press release contains “forward-looking statements,” including, but not limited to, geographic growth and the ability to deliver increasing value to all of the Company’s stakeholders.  No assurance can be given that the Company will grow geographically or be able to attract new agents.  Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including: risks in effectively managing rapid growth in our business; risks associated with making and integrating acquisitions; reliance on key personnel; technology risks; competitive risks; and the others set forth in the Risk Factors section of the Company’s registration statement for its initial public offering filed with the SEC.  Copies are available on the SEC’s website, www.sec.gov.  The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Investor Relations and Media Contacts:

Roger Pondel/Laurie Berman,
PondelWilkinson Inc.
[email protected] 
(310) 279-5980

Marco Fregenal
President and CFO
Fathom Holdings Inc.
[email protected]
(888) 455-6040

 

 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/fathom-holdings-enters-michigan-market-301194751.html

SOURCE Fathom Realty

Posted on

Xeriant Signs JV LOI with Coflow Jet to Develop Revolutionary “Green” Wing Technology

Advanced Airfoil’s Ultra High Lift and Efficiency Could Transform Aviation

BOCA RATON, Fla., Dec. 17, 2020 (GLOBE NEWSWIRE) — Xeriant, Inc. (OTC PINK: XERI), a new aerospace technology holding company, announced today that it has signed a letter of intent to form a joint venture with CoFlow Jet, LLC (“CoFlow”), a leading innovator in the field of high-performance airfoils, to further develop and commercialize CoFlow’s revolutionary active flow control airfoil technology, which promises to dramatically improve the lift capability and cruise efficiency of fixed wing aircraft. This innovation stands to play a key role in the nascent eVTOL (electric vertical takeoff and landing) aircraft segment, projected to reach $1.5 trillion by 2040, based on a 2019 Morgan Stanley report.

An emerging field of fluid dynamics, active flow control (AFC) in aircraft applications is the on-demand manipulation of airflow around aircraft structures. AFC techniques are generally aimed at reconfiguring airflow over the surface of the aircraft, which can have a substantial effect on flight performance. Augmenting lift, reducing drag, and removing or delaying flow separation at low energy expenditure will significantly boost overall aircraft performance with greater efficiency and noise suppression.

CoFlow’s patented AFC technology is specifically focused on altering the airflow characteristics of the most fundamental element enabling flight, the aircraft wing, and has the potential to significantly increase the mission productivity and efficiency of aircraft, and remove or replace conventional wing control surfaces such as flaps, slats and ailerons. As a unique technology, CoFlow’s robust, energy-efficient and reliable AFC actuation system produces the control authority needed to enhance wing aerodynamic performance throughout the entire flight regime, including takeoff, climb, cruise, descent, landing and maneuvers.

“Our company is tremendously impressed with Dr. Zha and his team’s commitment to revolutionizing aircraft wing design and the aviation industry. CoFlow’s disruptive airfoil technology represents a generational breakthrough and will transform the aerodynamic capabilities of fixed wing aircraft. Xeriant has been in discussions with CoFlow over the past year, and this LOI is an important step in furthering our relationship. We anticipate having a definitive JV agreement within the next few weeks,” stated Xeriant CEO, Keith Duffy.

The CoFlow AFC airfoil utilizes powerful, energy efficient wing-embedded micro-compressor actuators to inject pressurized air over the wing surface through a suction and injection system. To create the desired circulation and momentum, a small amount of air is suctioned at the wing’s trailing edge, energized, and injected tangentially at the leading edge. Wind tunnel tests and CFD simulations have demonstrated that CoFlow’s AFC airfoil creates a super-suction effect due to extremely low leading edge pressure, achieving an unprecedented stall angle of attack of 70 degrees or more, while typical airfoils reach maximum lift in the range of 15 to 18 degrees.

Among the benefits of a fully integrated aircraft with CoFlow’s AFC airfoil system are increased mission efficiency, augmented lift, reduced drag, better maneuverability, vertical takeoff and landing (VTOL), extremely short takeoff and landing (ESTOL) distance, low speed flight, noise reduction, improved high-altitude performance, faster takeoff and climb, less mechanical complexity, longer flight range, slower landing approach speeds, reduced structure weight, smaller control surfaces, decreased operating costs and a heavier payload.  Electrically-powered aircraft, which need to be fully optimized for efficiency due to the low energy density of batteries, will particularly benefit from this technology.

CoFlow’s AFC airfoil technology was developed over a period of 15 years by Dr. Gecheng Zha, Professor and Director of Aerodynamics and CFD Lab at the University of Miami’s Department of Mechanical and Aerospace Engineering. A NASA NIAC Fellow, ASME Fellow and AIAA Associate Fellow, Dr. Zha was recently recognized as one of the World’s Top 2% of Scientists in Aerospace and Aeronautics for 2020 based on the standardized citation metrics organized by Stanford University.

A strong proponent of green aviation, Dr. Zha has collaborated with DARPA, NASA, NSF and the U.S. Air Force on AFC as well as other projects over his impressive career, including the Mars Mission. Dr. Zha has also designed two innovative electric V/STOL (vertical and/or short takeoff and landing) aircraft concepts which incorporate CoFlow’s AFC airfoil technology. Upon completion of its AFC airfoil development, plan for integration, and FAA certification, CoFlow will begin commercialization, most likely through licensing arrangements with aircraft manufacturers.

“We look forward to securing the necessary funding to complete the development of our technology and bring it to market. CoFlow’s superior technology will become an integral component of future aircraft, as the industry moves toward reducing its carbon footprint,” commented CoFlow President and Founder, Gecheng Zha, PhD.

ABOUT XERIANT

Xeriant, Inc. (d.b.a. Xeriant Aerospace) is a holding and operating company focused on acquiring, developing, and commercializing revolutionary, eco-friendly technologies with applications in aerospace, including innovative aircraft concepts targeting emerging opportunities within the aviation industry. In 2019, Xeriant acquired a unique, scalable, multi-purpose VTOL aerial platform called Halo, which is protected under a broad utility patent. Xeriant is located at the Research Park at Florida Atlantic University in Boca Raton, Florida adjacent to the Boca Raton Airport. The Company is an OTC Markets public company trading under the stock symbol, XERI. 

For further information about Xeriant, please visit www.xeriant.com.

ABOUT COFLOW JET

CoFlow Jet, LLC is a green aerospace technology company and industry leader in the development of advanced active flow control systems focused on optimizing the aerodynamic properties of airfoils and aircraft wings, with the goal of making aviation more sustainable. CoFlow has also developed several innovative electric aircraft concepts designed for the emerging urban air mobility market. CoFlow is based in Miami, Florida, and has multiple patents in the U.S. and internationally.

SAFE HARBOR FORWARD-LOOKING STATEMENTS

In connection with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Xeriant, Inc. is hereby providing cautionary statements identifying important factors that could cause our actual results to differ materially from those projected in forward-looking statements (as defined in such act). Any statements that are not historical facts and that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, indicated through the use of words or phrases such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “intends,” “plans,” “believes” and “projects”) may be forward-looking and may involve estimates and uncertainties which could cause actual results to differ materially from those expressed in the forward-looking statements. These statements include, but are not limited to, our expectations concerning our ability to attract investors.

We caution that the factors described herein could cause actual results to differ materially from those expressed in any forward-looking statements we make and that investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time, and it is not possible for us to predict all of such factors. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

XERIANT, INC. CORPORATE

Keith Duffy, CEO
Innovation Centre #1
3998 FAU Blvd., Suite 309
Boca Raton, FL 33431
561-491-9595
[email protected]
www.xeriant.com



Posted on

Perrigo to Present Virtually at Upcoming Investor Conferences

PR Newswire

DUBLIN, Dec. 17, 2020 /PRNewswire/ — Perrigo Company plc (NYSE; TASE: PRGO), today announced that EVP and President of Consumer Self-Care Americas, Rich Sorota will present at the ICR Conference at 11:30 AM EST on Monday, January 11, 2021.

Perrigo President & CEO Murray S. Kessler and CFO, Ray Silcock, will present at the 39th Annual J.P. Morgan Global Healthcare Conference at 3:40 PM EST on Wednesday, January 13, 2021. Interested parties can access the presentation webcasts at http://perrigo.investorroom.com/events-webcasts.


About Perrigo

Perrigo Company plc (NYSE; TASE: PRGO) is a leading provider of Quality, Affordable Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Led by its consumer self-care strategy, Perrigo is the largest store brand OTC player in the U.S. in the categories in which it competes through more than 9,000 SKUs under customer ‘own brand’ labels. Additionally, Perrigo is a Top 5 OTC company by revenue in Europe, where it markets more than 200 branded OTC products throughout 28 countries. The Company also commercializes and manufactures generic prescription products in the U.S. Visit Perrigo online at www.perrigo.com. 


Forward-Looking Statements

Certain statements in this press release are “forward-looking statements.” These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “forecast,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or the negative of those terms or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company’s control, including: the effect of the novel coronavirus (COVID-19) pandemic and the associated economic downturn and supply chain impacts on the Company’s business; general economic, credit, and market conditions; future impairment charges; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than the Company does; pricing pressures from customers and consumers; resolution of uncertain tax positions, including the Company’s appeal of the Notice of Assessment (the “NoA”) issued by the Irish tax authority and the draft and final Notices of Proposed Assessment (“NOPAs”) issued by the U.S. Internal Revenue Service and the impact that an adverse result in any such proceedings would have on operating results, cash flows, and liquidity; pending and potential third-party claims and litigation, including litigation relating to the Company’s restatement of previously-filed financial information and litigation relating to uncertain tax positions, including the NoA and the NOPAs; potential impacts of ongoing or future government investigations and regulatory initiatives; potential costs and reputational impact of product recalls or sales halts; the impact of tax reform legislation and healthcare policy; the timing, amount and cost of any share repurchases; fluctuations in currency exchange rates and interest rates; the consummation of announced acquisitions or dispositions and the success of such transactions, and the Company’s ability to realize the desired benefits thereof; and the Company’s ability to execute and achieve the desired benefits of announced cost-reduction efforts and strategic and other initiatives. An adverse result with respect to our appeal of any material outstanding tax assessments or pending litigation, including securities or drug pricing matters, could ultimately require the use of corporate assets to pay such assessments, damages from third-party claims, and related interest and/or penalties, and any such use of corporate assets would limit the assets available for other corporate purposes. Statements regarding the separation of the Rx business, including the expected benefits, anticipated timing, form of any such separation and whether the separation ultimately occurs, are all subject to various risks and uncertainties, including future financial and operating results, our ability to separate the business, the effect of existing interdependencies with our manufacturing and shared service operations, and the tax consequences of the planned separation to the Company or its shareholders. These and other important factors, including those discussed under “Risk Factors” in the Company’s Form 10-K for the year ended December 31, 2019, as well as the Company’s subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/perrigo-to-present-virtually-at-upcoming-investor-conferences-301195068.html

SOURCE Perrigo Company plc

Posted on

DZS Strengthens Commitment to Open Standards and Freedom of Choice with Expanded Standards Body Relationships

Technology leader joins O-RAN Alliance and Telecom Infra Project and continues close relationship with Broadband Forum

PLANO, Texas, Dec. 17, 2020 (GLOBE NEWSWIRE) — DZS (NASDAQ: DZSI), a global leader of mobile, fixed broadband and enterprise access networking solutions representing 1,000+ communications service providers and enterprise customers, today reinforced its commitment to open standards and cross-industry collaboration by announcing its support of the O-RAN Alliance, Broadband Forum, and Telecom Infra Project.

“Network operators, our fellow ecosystem participants and end users alike view freedom of choice and open, software-driven systems to be the key ingredient of modern networks and services – whether its 5G, optical broadband and Fiber-to-the-Premises, smart cities, connected homes, or Internet of Things,” said Andrew Bender, CTO & Business Development Leader of DZS. “By investing in open standards and technology partnerships through organizations like O-RAN Alliance, Broadband Forum and Telecom Infra Project, DZS aligns with other like-minded innovators and ecosystem initiatives driving transformation in the communications industry. Our groundbreaking partnership with Rakuten to build what we believe is the world’s first fully virtualized, cloud-native mobile network supporting the Open RAN (O-RAN) architectural model is just one example of how DZS is enabling service providers worldwide to leverage open architectures and software-defined approaches to evolve fixed and mobile broadband networks, enable new services and improve the experience for both our customers, and the subscribers to these networks.”

Already an industry leader with its standards-based products and architectures, DZS is advancing a commitment to openness and interoperability through engagement with prominent standards bodies:

  • O-RAN Alliance – Along with partner and new member Rakuten Mobile, DZS has joined the O-RAN Alliance to progress the realization of technology, standards, and interoperation of O-RAN aligned implementations. Founded in 2018, the O-RAN Alliance is transforming the Radio Access Network towards an open, intelligent, virtualized and software-defined RAN architecture and ecosystem
  • Broadband Forum – DZS has renewed its Principal Vendor membership in Broadband Forum, the broadband industry’s leading standards and interoperability organization. With projects spanning 5G, Connected Home, CloudCO, and Access, DZS is in close alignment with virtually every aspect of its work. DZS has been active in Broadband Forum historically, both as a Silver Sponsor and frequent speaker in its Broadband Acceleration Seminar (BASe) series as well as a major contributor to its Cloud Central Office (CloudCO) and Open Broadband – Broadband Access Abstraction (OB-BAA) initiatives and demonstrations.
  • Telecom Infra Project (TIP) – Reflecting its longstanding commitment to customer freedom of choice, DZS has joined the TIP. Originally founded by Facebook in 2016, this global community of organizations is working to accelerate development, testing and deployment of open, disaggregated and standards-based connectivity platforms for fixed, mobile, and non-terrestrial access and transport networks.

With its forward-looking business strategy centered on open standards, joint ecosystem partnerships and enabling software-defined networks and services, DZS empowers its customers with freedom of choice and the agility to pursue open networks and best-in-class solutions. The future of 5G mobile edge access, broadband access, and the customer premises is clearly aligned with open solutions implemented on flexible, highly scalable and interoperable networks without vendor lock-in concerns. As a key participant in TIP, O-RAN Alliance, and Broadband Forum, DZS is actively turning the promise of this future into reality.

About DZS

DZS Inc. (NSDQ: DZSI) is global leader of mobile, fixed broadband and enterprise access networking and transport solutions with 20+ million products deployed across 1,000+ communication service providers and enterprise customers spanning 100+ countries.

DZS, the DZS logo, and all DZS product names are trademarks of DZS Inc. Other brand and product names are trademarks of their respective holders. Specifications, products, and/or product names are all subject to change.

This press release contains forward-looking statements regarding future events and our future results that are subject to the safe harbors created under the Private Securities Litigation Reform Act of 1995. These statements reflect the beliefs and assumptions of the Company’s management as of the date hereof. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “project,” “seek,” “should,” “target,” “will,” “would,” variations of such words, and similar expressions are intended to identify forward-looking statements. Readers are cautioned that these forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions that are difficult to predict. The Company’s actual results could differ materially and adversely from those expressed in or contemplated by the forward-looking statements. Factors that could cause actual results to differ include, but are not limited to, those risk factors contained in the Company’s SEC filings available at www.sec.gov, including without limitation, the Company’s annual report on Form 10-K, quarterly reports on Form 10-Q and subsequent filings. In addition, additional or unforeseen affects from the COVID-19 pandemic and the global economic climate may give rise to or amplify many of these risks. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date on which they are made. DZS undertakes no obligation to update or revise any forward-looking statements for any reason.

For further information see: www.DZSi.com.
DZS on Twitter: https://twitter.com/dzs_innovation
DZS on LinkedIn: https://www.linkedin.com/company/DZSi/

Press Inquiries:

McKenzie Hurst, Thatcher+Co.
Mobile: +1 408.888.6787
Email: [email protected] 



Posted on

Allscripts Moves Quickly to Support Clients in COVID-19 Vaccine Administration

Allscripts Moves Quickly to Support Clients in COVID-19 Vaccine Administration

Company offers guidance to track and report vaccine administration to the CDC

CHICAGO–(BUSINESS WIRE)–
Allscripts Healthcare Solutions (NASDAQ MDRX) is dedicating extensive resources to ensure its clients are prepared to maximize functionality within its solutions to respond to the COVID-19 pandemic.

Allscripts has collaborated with public health officials at all levels, including the United States Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention (CDC), and the American Immunization Registry Association (AIRA) to address the urgent need to capture and report vaccine administration. Since 2011, Allscripts Electronic Health Record (EHR) solutions have supported vaccine administration, associated reminders and reporting to state immunization registries in compliance with the Office of the National Coordinator for Health Information Technology (ONC) certification requirements.

In addition, in consideration of the new requirements associated with COVID-19 vaccinations, Allscripts is delivering capabilities to clients that include orders, billing, reporting, allergy/intolerance/adverse events and second-dose reminders, and importantly, data that can be uploaded with the new vaccine information. New CPT codes and relevant medications will also be addressed. Allscripts has also implemented functionality to ensure that clients can document the first administered vaccines in their Allscripts EHRs, with no need to use other external databases or disparate data logged into spreadsheets.

“As has been the case for nearly two decades, Allscripts has proven that it is a trusted partner in helping us provide exceptional care to our patients during this challenging pandemic,” said Jim West, PIH Health System President and Chief Executive Officer. “We know Allscripts is by our side in tackling the critically important health IT-managed tasks related to the COVID-19 vaccine administration.”

“Through the course of the pandemic, Allscripts has collaborated with HHS, the CDC, state governments, public health organizations and others to best prepare our clients for the challenges associated with delivering care during the COVID-19 pandemic, which now happily includes vaccine administration tasks,” said Allscripts Chief Executive Officer, Paul Black. “We’re working together to deliver solutions that provide our clients with the information and decision support tools they need at the point of care, recognizing the incredible challenge facing the country to inoculate hundreds of millions of people against the virus in as short a time as humanly feasible. Allscripts is committed to assisting our clients in increasing the vaccination coverage and eagerly answering our collective obligation to better arm our caregivers in the fight against the spread of COVID-19.”

About Allscripts

Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTubeand It Takes a Community: The Allscripts Blog.

© 2020 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

Investors:

Stephen Shulstein

312-386-6735

[email protected]

Media:

Concetta Rasiarmos

312-447-2466

[email protected]

KEYWORDS: Illinois United States North America

INDUSTRY KEYWORDS: Technology Infectious Diseases Hospitals Software Networks Practice Management Managed Care Pharmaceutical Health Data Management

MEDIA:

Logo
Logo
Posted on

Unity and Snap Inc. Partner to Extend Ad and Tech Reach

Unity and Snap Inc. Partner to Extend Ad and Tech Reach

Unity Ads now available in the Snap Audience Network; Snap Kit SDK now available for Unity game developers, with Bitmoji for Games SDK coming in 2021

SAN FRANCISCO–(BUSINESS WIRE)–Unity (NYSE: U), the world’s leading platform for creating and operating real-time 3D (RT3D) content, and Snap Inc. (NYSE: SNAP) today announced a partnership that extends the reach of Unity’s Ads supply to Snapchat advertisers, and brings Snap technology to game developers through Snap Kit. With more than 50 percent of all mobile games made with Unity, the Unity and Snapchat advertising and game development integrations fortify reach to the mobile gaming audience, and the discoverability of mobile games, across both platforms.

“We’re building on our commitment of enabling developer success at all stages of the game life cycle, from creation onwards,” said Julie Shumaker, Vice President of Revenue, Operate Solutions, Unity. “Snap brings their vast advertiser community to the Unity ecosystem where they will reach highly engaged and valuable player audiences, while the verified elements from Snap used in games made with Unity will allow players to drive social sharing and game discovery.”

Starting today, Unity Ads, which reaches a highly engaged mobile gaming audience on both Android and iOS, is now included in the Snap Audience Network (SAN). Snapchat’s SAN advertiser campaigns will now include video inventory from Unity’s extensive network of mobile gaming titles, helping advertisers extend beyond Snapchat. Unity Ads1 reports 22.9B+ monthly global ad impressions, reaching 2B+ monthly active end-users worldwide. In 2020, mobile ad viewers have converted at higher frequencies, with install conversion rates up by 23%2, and mobile gamers installing 84% more apps3.

“Snapchat is all about staying connected with your closest friends, but friendships aren’t just about conversations. They are often also based on shared experiences, which today includes gaming,” said Ben Schwerin, VP of Partnership, Snap Inc. “As gaming has increasingly become a visible part of the Snapchatter journey, it’s also an area that we aim to make easier for retailers and brands to reach Unity’s action-orientated gaming community through their Snapchat campaigns.”

Available today in the Unity Asset Store, mobile game developers can also now leverage select features of Snap Kit to enhance gameplay and the game discovery experience:

  • Snap Kit’s Login Kit allows gamers to use their Snapchat account as a quick way to sign up and log in to games.
  • Snap Kit’s Creative Kit extends the experience by allowing users to share their gameplay, decorating still shots or 15-second videos with branded stickers, or attaching an AR lens that has been created with game branding to share with their Snapchat friends. The shares also include referral links back to the game, amplifying discovery and user acquisition for Unity developers to Snapchat’s 249 million daily active users4.

A Bitmoji integration will also be coming in early 2021, and will add a new level of personalization to gameplay. With Bitmoji for Game’s Unity SDK, developers will be able to leverage 3D Bitmoji to create a more immersive experience in games made with Unity. They will be able to bring players’ Bitmoji avatars into the center of gameplay, enabling players to be themselves in games like never before.

Both the Snap Kit and Bitmoji SDKs are offered via Unity’s Verified Solutions Partner program which includes third-party SDKs, plugins, editor applications, cloud services and more solutions that are verified to comply with Unity’s latest releases to ensure developers can integrate an offering with minimal effort.

“There are games for all types of unique social situations and social groups,” added Schwerin. “The Snap Kit and Bitmoji integrations with Unity will unlock many new opportunities for game developers to reach audiences by allowing them to more easily share experiences with one another while increasing visibility of their games.”

The integration of Unity Ads into the Snap Audience Network is available in the US and Canada, with more countries to come soon. Snap Kit’s Login Kit and Creative Kit features are available today worldwide. The Bitmoji Kit integration will be available in early 2021.

To learn more about Unity Ads, please visit https://unity.com/solutions/unity-ads. To learn more about Unity’s VSP Program, please visit https://unity.com/partners/verified-solutions.

About Unity

Unity (NYSE: U) is the world’s leading platform for creating and operating real-time 3D (RT3D) content. Creators, ranging from game developers to artists, architects, automotive designers, filmmakers, and others, use Unity to make their imaginations come to life. Unity’s platform provides a comprehensive set of software solutions to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The company’s 1,800+ person research and development team keeps Unity at the forefront of development by working alongside partners to ensure optimized support for the latest releases and platforms. Apps developed by Unity creators were downloaded more than five billion times per month in 2020. For more information, please visit www.unity.com.

1 Numbers reported as of the six months ending June 30, 2020.

2 Source: Unity report; “COVID-19’s Impacts on the Gaming Industry: 19 Takeaways” www.unity.com/covid19-report.

3 Source: Unity report; “COVID-19’s Impacts on the Gaming Industry: 19 Takeaways” www.unity.com/covid19-report.

4 Snap Inc. internal data Q3 2020. See Snap Inc. public filings with the SEC.

Marisa Graves

Unity Communications

[email protected]

+1 215-801-2485

Ryan M. Wallace

Unity Communications

[email protected]

+1 917-442-2305

KEYWORDS: California North America United States Ireland United Kingdom Europe

INDUSTRY KEYWORDS: Technology Other Communications Electronic Games Online Marketing Advertising Entertainment Communications Social Media Software Mobile/Wireless

MEDIA:

Logo
Logo
Posted on

blumshapiro Team Members to Join CLA, Expanding Opportunity in Northeast

As CLA, team members to optimize seamless experience for clients, team members, and communities

Hartford, CT, Dec. 17, 2020 (GLOBE NEWSWIRE) — Top 100 firm Blum, Shapiro & Company, P.C. (blumshapiro) team members intend to join national professional services firm CLA (CliftonLarsonAllen LLP) on January 1, 2021.

blumshapiro is the largest regional business advisory firm based in New England. blumshapiro’s tax, accounting, audit, and advisory teams use their subject matter and industry experience, built over the past 35 years, to serve private companies, nonprofits, and government organizations.

CLA, named to Accounting Today’s top 10 accounting firms, is an industry-focused wealth advisory, outsourcing, audit, tax, and consulting services firm with experience across a spectrum of industries.

CLA will now have more than 7,000 people in 130+ locations across 31 states. 

“At blum, we help clients create what’s next by providing a platform to imagine the possibilities,” said Joseph Kask, blumshapiro chief executive officer. “In CLA, we’ve found a team who shared our vision for the future and embraced our values through a common culture. Together we will create opportunities for our clients, people, and communities.”

“With the addition of the blum team, our ability to attract and retain talent increases exponentially,” said Denny Schleper, CLA CEO. “It’s a tremendous advantage for our clients, underscoring our commitment to create inspired careers with channels for growth, success, and personal satisfaction.”

Allan D. Koltin, CEO of Koltin Consulting Group, who advised both firms on the combination, commented, “CLA continues its journey as one of the nation’s largest and most successful firms. They have stayed true to their culture and ‘quietly’ are one of the most profitable firms in the country and the envy of the profession.”

The 500+ former blum team members will continue to serve clients locally and nationally from locations in Connecticut, Massachusetts, Rhode Island, and Virginia, increasing CLA’s presence in the region to more than 1,150 people.

About CLA

CLA exists to create opportunities for our clients, our people, and our communities through industry-focused wealth advisory, outsourcing, audit, tax, and consulting services. With more than 6,500 people, 130 U.S. locations and a global affiliation, we promise to know you and help you. For more information, visit CLAconnect.com. Investment advisory services are offered through CliftonLarsonAllen Wealth Advisors, LLC, an SEC-registered investment advisor.

About blumshapiro

blumshapiro is the largest regional business advisory firm based in New England, with offices in Connecticut, Massachusetts, Rhode Island, and Virginia. The firm, with a team of over 500, offers a diversity of services, which include auditing, accounting, tax, and business advisory services. blum serves a wide range of privately held companies, government, and nonprofit organizations and provides non-audit services for publicly traded companies. To learn more visit us at blumshapiro.com.



Jackie Kruger
CLA (CliftonLarsonAllen LLP)
612-376-4623
[email protected]